semipreparative column (Macherey-Nagel), protected by a 5 cm guard column of identical stationary phase. The flow rate of mobile phase was 9 mL/min and the UV detection wavelength was 254 nm.
The middle segment of the [ 
Analytical HPLC and quality control
The HPLC equipment used for determination of chemical and radiochemical purity of the final injectable [ 
Radiometabolite analysis
Heparinized arterial blood samples (5 mL) collected 1, 1. Varifuge RF centrifuge (10'000 g, 5 min). The resulting plasma supernatant of each sample was transferred into test tubes containing 5 mL of acetic acid 50 mM spiked with 2 µMol (non labelled, "cold") altanserin. After vortexing for 2 min, diluted plasma samples were slowly passed through Waters C-18 SepPak Light cartridges pre-conditioned with 10 mL ethanol and 10 mL water. After drying under a stream of nitrogen for 1 min, the extraction columns were washed with 20 mL water, dried anew and the parent tracer and metabolites eluted into HPLC vials with 1.5 mL methanol. For determination of tracer-and metabolite recovery ("activity balance"), total activity of original plasma samples, washing solutions and eluates were determined by use of a Packard COBRA II auto-gamma counter.
The isocratic HPLC method used for quality control purposes (see 2.3 "Analytical HPLC") was used also for chromatographic separation of parent tracer and active [ 18 F]altanserin metabolites. Injection volume was 400 µL. For each sample, two fractions of eluate were collected in test tubes: fraction 1 (containing all active altanserin metabolites) was collected from t 0 (time of injection) to the onset of the altanserin UV-peak (arising from sample spiking) and fraction 2 (containing authentic tracer) was collected from the onset of altanserin peak to t 0 + 6 min. Radioactivity in the fractionated HPLC eluates was quantitatively determined in the gamma counter. and no additional peaks appeared in the chromatograms.
Results and discussion

Synthesis and quality control
Previously published synthesis procedures involved microwave heating [Lemaire et al., 1991; Monclus et al., 1998; Tan et al., 1999] or thermal heating in an electrochemical cell [Hamacher and Coenen, 2006] . Chemical yields using these procedures are reported to be higher (20 -25%), but automation of microwave heating is considered technically complicated [Lemaire et al., 1991] . We see the use of conventional thermal heating using a thermostat-regulated heating lamp as a technically simple and easily implementable alternative for routine production of [ 18 F]altanserin. According to our experience, exhaustive azeotropic distillation in order to ensure complete absence of water in the reaction vessel is the most critical point for successful production of [ 18 F]altanserin.
Metabolite analysis and metabolite corrected [ 18 F]altanserin time-activity curve
Blood to plasma radioactivity ratio determined in human blood samples collected between 1 und 90 min after bolus injection of 250 MBq [ to plasma ratio remained unchanged despite the appearance of metabolites in the blood stream. Our findings confirm earlier data provided by Biver et al. [Biver et al., 1994] . Table 2 shows recovery rates from radiometabolite solid phase extractions (mean ± SD, N=6). Summing up data from 4 different sampling times (1, 5, 30 and 60 min. following start of bolus tracer injection), > 97.8 % of total plasma radioactivity is retained on solid phase cartridge during sample passage, < 0.2 % of activity is lost due to washing of the cartridge, and 4.7 ± 2.6 % of total activity remains on cartridge after metabolite elution with methanol. 93.7 ± 2.6 % of total radioactivity in the arterial plasma samples is eluted into the vials and available for metabolite separation by HPLC. Mean overall recovery for all 4 samples is 100.1 ± 1.4 %. Metabolism of [ Residual activity on cartridge 4.4 ± 2.6 Residual activity on cartridge 5.5 ± 2.9 
Overall
